New hope for bladder cancer patients who can't take chemo

NCT ID NCT02845323

Ongoing Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two immunotherapy drugs (nivolumab with or without urelumab) given before bladder removal surgery in 15 patients with muscle-invasive bladder cancer who cannot or refuse standard chemotherapy. The goal is to see if adding urelumab boosts the immune response against the tumor. Participants are randomly assigned to receive either the combination or nivolumab alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma transitional cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER UROTHELIAL CARCINOMA

Contacts and locations

Locations

Columbia University Medical Center

New York, New York, 10032, United States
Johns Hopkins Hospital

Baltimore, Maryland, 21205, United States
UCLA Institute of Urologic Oncology

Los Angeles, California, 90095, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Colorado Cancer Center

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.